Equities analysts expect that Trillium Therapeutics Inc (NASDAQ:TRIL) (TSE:TR) will report earnings of ($0.42) per share for the current quarter, according to Zacks. Zero analysts have issued estimates for Trillium Therapeutics’ earnings. The lowest EPS estimate is ($0.43) and the highest is ($0.40). Trillium Therapeutics posted earnings per share of ($0.51) during the same quarter last year, which would indicate a positive year over year growth rate of 17.6%. The firm is scheduled to announce its next quarterly earnings report on Friday, May 10th.
On average, analysts expect that Trillium Therapeutics will report full-year earnings of ($1.90) per share for the current financial year, with EPS estimates ranging from ($2.43) to ($1.67). For the next financial year, analysts expect that the company will report earnings of ($1.21) per share, with EPS estimates ranging from ($1.61) to ($0.74). Zacks Investment Research’s EPS averages are a mean average based on a survey of analysts that that provide coverage for Trillium Therapeutics.
Trillium Therapeutics (NASDAQ:TRIL) (TSE:TR) last posted its earnings results on Monday, March 11th. The biotechnology company reported ($0.42) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.66) by $0.24.
TRIL traded up $0.03 during trading on Friday, reaching $0.60. 1,133,403 shares of the stock were exchanged, compared to its average volume of 827,352. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.56 and a current ratio of 3.56. The company has a market cap of $8.85 million, a price-to-earnings ratio of -0.26 and a beta of 2.29. Trillium Therapeutics has a 1 year low of $0.51 and a 1 year high of $7.50.
Several large investors have recently modified their holdings of the company. Morgan Stanley lifted its position in shares of Trillium Therapeutics by 25.2% in the third quarter. Morgan Stanley now owns 356,655 shares of the biotechnology company’s stock valued at $2,068,000 after acquiring an additional 71,860 shares in the last quarter. Geode Capital Management LLC increased its stake in Trillium Therapeutics by 164.0% in the fourth quarter. Geode Capital Management LLC now owns 26,627 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 16,541 shares during the last quarter. Jane Street Group LLC acquired a new position in Trillium Therapeutics in the fourth quarter valued at $43,000. Finally, Two Sigma Investments LP acquired a new position in Trillium Therapeutics in the fourth quarter valued at $35,000. Institutional investors and hedge funds own 39.43% of the company’s stock.
Trillium Therapeutics Company Profile
Trillium Therapeutics Inc, a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trials for advanced hematologic malignancies, and solid tumors and mycosis fungoides.
See Also: What is a Stop Order?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Trillium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.